Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence
Status:
Recruiting
Trial end date:
2022-09-28
Target enrollment:
Participant gender:
Summary
Our long-term objective is to evaluate the efficacy of curcumin (CC) in preventing a
recurrence of chronic subdural hematoma (cSDH) following surgical evacuation. Recurrence is
defined as an increase in total hematoma volume on the operated side compared to a
post-operative day one CT scan with persistent or recurrent neurological symptoms. The
investigators propose this pilot study to assess feasibility and obtain preliminary benefit
assessment of the proposed therapeutic approach.
Objective 1: To determine if the use of CC treatment reduces the total hematoma cavity volume
over a 6-month interval, compared to a post-subdural drain removal CT scan. This evaluation
is expected to offer sufficient evidence for a larger definitive trial.
Objective 2: Study the effect of CC on interleukin-8 (IL-8)-induced disruption of endothelial
permeability in vitro using human vascular endothelial cells.
Central hypothesis: CC treatment prevents the re-accumulation of cSDH, which may occur by
inhibition of IL-8 and allowing resolution of the total hematoma cavity volume over six
months.